|
1
|
Richette P, Latourte A and Bardin T:
Cardiac and renal protective effects of urate-lowering therapy.
Rheumatology (Oxford). 57 suppl_1:i47–i50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Foody J, Turpin RS, Tidwell BA, Lawrence D
and Schulman KL: Major cardiovascular events in patients with gout
and associated cardiovascular disease or heart failure and chronic
kidney disease initiating a xanthine oxidase inhibitor. Am Health
Drug Benefits. 10:393–401. 2017.PubMed/NCBI
|
|
3
|
Kim Y, Oh HC, Park JW, Kim IS, Kim JY, Kim
KC, Chae DS, Jo WL and Song JH: Diagnosis and treatment of
inflammatory joint disease. Hip Pelvis. 29:211–222. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anandh U and Jayanna K: Nontubercular
mycobacterial infection in a renal allograft recipient. Indian J
Nephrol. 27:478–481. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Beslon V, Moreau P, Maruani A, Maisonneuve
H, Giraudeau B and Fournier JP: Effects of discontinuation of
urate-lowering therapy: A systematic review. J Gen Intern Med.
33:358–366. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruiz Perez F, Sanchez-Piedra CA,
Sanchez-Costa JT, Andres M, Diaz-Torne C, Jimenez-Palop M, De
Miguel E, Moragues C and Sivera F: Improvement in diagnosis and
treat-to-target management of hyperuricemia in gout: Results from
the GEMA-2 transversal study on practice. Rheumatol Ther.
5:243–253. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones G, Panova E and Day R: Guideline
development for the management of gout: Role of combination therapy
with a focus on lesinurad. Drug Des Devel Ther. 11:3077–3081. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue
K, Sugimoto M, Hidaka Y, Taniguchi A, Fujimori S and Yamamoto T:
Stepwise dose increase of febuxostat is comparable with colchicine
prophylaxis for the prevention of gout flares during the initial
phase of urate-lowering therapy: Results from FORTUNE-1, a
prospective, multicentre randomised study. Ann Rheum Dis.
77:270–276. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou C, Xue C, Yang B, Wang W, Xu Y, Huang
F and Wang Y: Amputation of the first metatarsophalangeal joint due
to a giant gouty tophi: A case report. Medicine (Baltimore).
96:e84412017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sheer R, Null KD, Szymanski KA, Sudharshan
L, Banovic J and Pasquale MK: Predictors of reaching a serum uric
acid goal in patients with gout and treated with febuxostat.
Clinicoecon Outcomes Res. 9:629–639. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Collison J: Crystal arthritis: Febuxostat
reduces synovitis in early gout. Nat Rev Rheumatol. 13:6942017.
View Article : Google Scholar
|
|
12
|
Cutolo M, Cimmino MA and Perez-Ruiz F:
Potency on lowering serum uric acid in gout patients: A pooled
analysis of registrative studies comparing febuxostat vs.
allopurinol. Eur Rev Med Pharmacol Sci. 21:4186–4195.
2017.PubMed/NCBI
|
|
13
|
Huneycutt E, Board C and Clements JN:
Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in
combination with a xanthine oxidase inhibitor, for hyperuricemia
associated with gout. J Pharm Pract. Jan 1–2017.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sanchez-Niño MD, Zheng-Lin B, Valiño-Rivas
L, Sanz AB, Ramos AM, Luño J, Goicoechea M and Ortiz A: Lesinurad:
What the nephrologist should know. Clin Kidney J. 10:679–687. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dalbeth N, Saag KG, Palmer WE, Choi HK,
Hunt B, MacDonald PA, Thienel U and Gunawardhana L: Effects of
febuxostat in early gout: A randomized, double-blind,
placebo-controlled study. Arthritis Rheumatol. 69:2386–2395. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davies K and Bukhari MAS: Recent
pharmacological advances in the management of gout. Rheumatology
(Oxford). 2017:1093–1096. 2017.
|
|
17
|
Plumpton CO, Alfirevic A, Pirmohamed M and
Hughes DA: Cost effectiveness analysis of HLA-B*58:01 genotyping
prior to initiation of allopurinol for gout. Rheumatology (Oxford).
56:1729–1739. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Britnell SR, Chillari KA and Brown JN: The
role of xanthine oxidase inhibitors in patients with history of
stroke: A systematic review. Curr Vasc Pharmacol. 2017:128–135.
2017.
|
|
19
|
Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um
TH, Cho CR and Han SY: Renoprotective effects of febuxostat
compared with allopurinol in patients with hyperuricemia: A
systematic review and meta-analysis. Kidney Res Clin Pract.
36:274–281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hill-McManus D, Soto E, Marshall S, Lane S
and Hughes D: Impact of non-adherence on the safety and efficacy of
uric acid-lowering therapies in the treatment of gout. Br J Clin
Pharmacol. 84:142–152. 2018. View Article : Google Scholar : PubMed/NCBI
|
